Your session is about to expire
← Back to Search
SEP-363856 for Major Depressive Disorder
Verified Trial
Phase 2 & 3
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have you been diagnosed with Major Depressive Disorder?
Have you tried at least one antidepressant that hasn't worked?
Must not have
Have you tried 4 or more antidepressants that haven't worked?
Have you been diagnosed with Schizophrenia or Bipolar Disorder or Borderline Personality Disorder or Antisocial Personality Disorder or PTSD or OCD or Panic Disorder or Eating Disorders?
Timeline
Screening 3 weeks
Treatment 8 weeks
Follow Up 1 week
Summary
A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Who is the study for?
Adults aged 18-65 with major depressive disorder (MDD) who are currently experiencing a depressive episode and have had an inadequate response to 1-3 antidepressant treatments. The current episode should be at least 8 weeks but no more than 2 years long.
What is being tested?
This trial is testing the safety and effectiveness of SEP-363856 as an additional treatment for MDD in adults.
What are the potential side effects?
While specific side effects for SEP-363856 aren't listed here, common side effects from depression medications may include nausea, headache, sleep disturbances, fatigue, dry mouth, blurred vision or dizziness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Timeline
Screening ~ 3 weeks3 visits
Treatment ~ 8 weeksup to 1 visit
Follow Up ~ 1 week1 call or visit
Screening ~ 3 weeks
Treatment ~ 8 weeks
Follow Up ~1 week
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Montgomery Åsberg Depression Rating Scale (MADRS)
Secondary study objectives
Clinical Global Impression - Severity of Illness (CGI-S)
Trial Design
2Treatment groups
Group I: SEP-363856 & ADT (Antidepressant Therapy)
Group II: Placebo & ADT (Antidepressant Therapy)
Group I: SEP-363856 & ADT (Antidepressant Therapy)Experimental Treatment1 Intervention
Group II: Placebo & ADT (Antidepressant Therapy)Placebo Group1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Common treatments for depression, such as SSRIs, SNRIs, TCAs, and atypical antipsychotics, primarily work by modulating neurotransmitter levels in the brain, particularly serotonin and norepinephrine. This modulation helps to improve mood and emotional stability, which is essential for alleviating depressive symptoms.
Understanding these mechanisms is important for patients as it provides insight into how these medications can help manage their condition and what side effects might be expected. This knowledge also aids clinicians in tailoring treatments to individual needs, enhancing the likelihood of successful outcomes.
Bulimia nervosa : a review of therapy research.Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided?
Bulimia nervosa : a review of therapy research.Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided?
Find a Location
Who is running the clinical trial?
Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
265 Previous Clinical Trials
168,187 Total Patients Enrolled
28 Trials studying Depression
39,319 Patients Enrolled for Depression
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 18 and 65 years old.I've tried 1-3 antidepressants without enough improvement.You currently have a diagnosed mental health condition such as bipolar disorder, eating disorder, or PTSD.My current major depressive episode has lasted between 8 weeks and 2 years.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo & ADT (Antidepressant Therapy)
- Group 2: SEP-363856 & ADT (Antidepressant Therapy)
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 8 Weeks
- Follow Ups: You may be asked to continue sharing information regarding the trial for 1 Weeks after you stop receiving the treatment.